Algorithmiq has raised USD4 million in seed funding round to make its quantum-enhanced drug discovery platform commercially available.
Algorithmiq has raised USD4 million in seed funding round to make its quantum-enhanced drug discovery platform commercially available.
The investors include Jorma Ollila (Nokia/Shell), Haakon Overli (Dawn Capital), Thames Trust (Lord Jim O’Neill), David Helgason (Foobar/Unity3D), Tiger Global, Feroz Dewan (Arena Holdings), Keenan Rice (Tokyo Black/LookerGoogle/Firebolt) and K5 Global and other European and US angels and entrepreneurs. 

Algorithmiq can boost the speed of chemical simulations on quantum computers by a factor of 100-times compared to current industry benchmarks and expands the universe of chemical simulations tractable on near-term quantum devices.
